Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results: A Case Report

    April 2020 in “ Journal of the Endocrine Society ”
    Parvathy Madhavan, Steven J. Shichman, Nitya Raj … Carl D. Malchoff
    Studysummary This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →